Synektik S.A.

Synektik S.A. Secures Major Contract for da Vinci Surgical System Installation

Synektik S.A., a leading Polish medical technology company, has signed a significant agreement with the Regional Specialist Hospital named after Dr. Władysław Biegański in Grudziądz. The contract, valued at PLN 12,884,425.54 net, involves the delivery, installation, and commissioning of the da Vinci robotic surgical system, along with adaptation works, personnel training, and warranty-period service support. The agreement was finalized following a public procurement process conducted through an open tender.

The delivery and installation of the da Vinci system are expected to be completed within 40 days of signing the contract, with a warranty period of 60 months starting from the final acceptance protocol. The deal represents 5% of Synektik Group's equity as reported in its latest financial statement, meeting the company's internal reporting standards for significant agreements. Revenue from this project will contribute to the financial results of FY2025, spanning from October 1, 2025, to September 30, 2026.

Relevance: This agreement underscores Synektik S.A.'s position as the exclusive distributor of the da Vinci robotic surgical system in Poland and highlights its role in advancing minimally invasive surgical technologies in the healthcare sector.

Robotic Surgery Revolutionizes Gynecological Procedures in Poland

Robotic surgery is transforming gynecological procedures in Poland, offering groundbreaking advancements in treating complex conditions such as deep infiltrating endometriosis, myomectomy, and early-stage ovarian cancer. Dr. Daniel Kurczyński from the Katowice Oncology Center highlights the significant benefits of robotic systems, particularly the da Vinci surgical platform, in enhancing surgical precision, reducing patient recovery time, and minimizing complications compared to traditional laparoscopic or open surgeries.

One of the key drivers of robotic surgery adoption in gynecology has been the increased reimbursement for endometrial cancer surgeries over the past 2.5 years. These procedures, which are standardized and relatively straightforward, have allowed hospitals to treat a larger number of patients with improved outcomes. Robotic systems provide superior visualization, ergonomic advantages for surgeons, and reduced trauma to tissues, leading to faster recovery and lower postoperative pain for patients. Additionally, robotic surgery is particularly advantageous for obese patients and those with complex anatomical challenges, such as multi-organ adhesions caused by endometriosis.

Dr. Kurczyński emphasizes the need for quality control and data collection in robotic surgery to ensure consistent outcomes and foster continuous improvement. He advocates for the use of surgical recordings and clinical registries to analyze and enhance surgical techniques, as well as to provide transparency for patients and healthcare providers. Furthermore, he underscores the importance of training younger surgeons in robotic systems to maximize the long-term benefits of this advanced technology.

Robotic surgery is also paving the way for innovative procedures, such as scar defect repair after cesarean sections and urogynaecological surgeries. However, challenges remain, including the higher costs associated with robotic systems and the need for better reimbursement models for complex procedures like endometriosis surgeries. Despite these hurdles, robotic surgery is poised to play a pivotal role in advancing gynecological care in Poland.

Relevance to Synektik S.A.: This article highlights the growing adoption and benefits of the da Vinci robotic surgical system, which Synektik S.A. exclusively distributes in Poland. It underscores the company's role in advancing medical technology and improving patient outcomes through innovative solutions.

Edge Medical Expands Robotic Surgery Market in Poland and Central Europe

Edge Medical, a Chinese manufacturer of surgical robots, has rapidly expanded its presence in Poland and Central Europe, achieving significant milestones in robotic surgery. Since receiving European certification in mid-2025, the company has installed five MP1000 multi-port robotic systems in Polish hospitals, including facilities in Kościerzyna, Mielec, Rzeszów, and Częstochowa. The company plans to introduce its single-port SP1000 system, which received European certification in late 2025, to Polish hospitals in 2026. The SP1000 system is designed for specialized procedures in urology, gynecology, thoracic surgery, and other fields, offering advanced technology at competitive costs.

Edge Medical has also established a robust training infrastructure, including a center in Otwock in collaboration with CMKP and another planned facility in Częstochowa. These centers aim to train surgeons in robotic systems, ensuring a smooth transition to advanced surgical technologies. Additionally, Edge Medical has pioneered tele-surgery in Poland, enabling remote operations and expanding the possibilities of robotic-assisted procedures. The company is also building a distribution network across eight Central European countries, including the Baltics, Czech Republic, and Romania, with plans for further installations and partnerships in 2026.

Despite growing competition in the Polish market, the da Vinci system remains the dominant player. However, Edge Medical is positioning itself as a strong competitor by offering cost-effective solutions, longer-lasting tools, and innovative technologies. The company’s focus on affordability, training, and technological advancements is expected to drive further adoption of robotic surgery in the region.

Relevance to Synektik S.A.: This article highlights the competitive landscape of the robotic surgery market in Poland, where Synektik S.A. is the exclusive distributor of the da Vinci surgical system. The emergence of Edge Medical as a competitor underscores the importance of Synektik's continued innovation and strategic positioning in the growing field of robotic-assisted surgery.

Hypertension: A Silent Epidemic Threatening Public Health

Hypertension, often referred to as the "silent killer," affects over 11 million Poles, making it a national health crisis. Despite the availability of effective and affordable medications, the disease remains poorly managed due to a lack of awareness, non-compliance with medical advice, and neglect of regular blood pressure monitoring. Experts emphasize that untreated hypertension is a leading cause of heart attacks, strokes, kidney failure, and premature deaths. Early detection, lifestyle changes, and adherence to prescribed therapies are critical to reversing this alarming trend.

Specialists advocate for systematic blood pressure screenings starting from childhood, as studies show that hypertension affects up to 5% of children and adolescents. Public health initiatives, such as the "Mission 50/30" campaign by the Polish Society of Hypertension, aim to ensure that by 2030, half of all hypertension patients achieve therapeutic goals. However, achieving this requires a collaborative effort between healthcare providers and patients, emphasizing education, regular monitoring, and adherence to treatment plans.

Lowering systolic blood pressure by just 10 mmHg can significantly reduce the risk of complications, including a 27% decrease in stroke risk and a 13% reduction in overall mortality. With consistent efforts, experts remain optimistic about improving outcomes and extending the lifespan of those affected by this chronic condition.

Relevance to Synektik S.A.: This article highlights the importance of advanced medical technologies and solutions, such as diagnostic imaging systems and IT platforms like those provided by Synektik S.A., in addressing public health challenges like hypertension through early detection and effective management.

Synektik S.A. Expands Robotic Surgery Portfolio and Strengthens Market Leadership

Synektik S.A., a leading Polish medical technology company, continues to solidify its position as a pioneer in robotic surgery solutions. By the end of 2025, the company had successfully installed 83 authorized da Vinci surgical systems in Polish hospitals, with an additional 38 installations across the Baltic states, Czech Republic, Slovakia, and Ukraine. In 2025 alone, Synektik completed 27 new installations and introduced the advanced da Vinci 5 model and Symani robots for microsurgery to the market. The company is also preparing to launch the single-port da Vinci SP system and the Ion robotic bronchoscopy system in 2026.

To address diverse hospital needs, Synektik offers a wide range of robotic systems, including refurbished da Vinci XiR models, which come with full warranties and service support. This initiative aligns with the company’s commitment to sustainability and affordability. Despite growing competition, particularly from Chinese manufacturers, Synektik emphasizes the superior quality, reliability, and cost-effectiveness of its systems, supported by Intuitive Surgical’s extensive R&D investments and global expertise.

Synektik’s efforts extend beyond sales, with a strong focus on training and support. The company has trained over 380 surgical teams in Poland and plans to open a new training center in Warsaw in collaboration with SGGW in 2026. Additionally, Synektik is driving the adoption of robotic systems in emerging fields such as pediatric surgery, head and neck surgery, and thoracic surgery, while continuing to enhance its offerings with advanced digital and AI functionalities.

Recognized as the "Distributor of the Year" in 2025 for its excellence in training, implementation, and service, Synektik remains committed to advancing robotic surgery and improving patient outcomes. With over 20 million da Vinci procedures performed globally and a robust support system, the company is well-positioned to maintain its leadership in the rapidly evolving medical robotics market.

Relevance to Synektik S.A.: This article highlights Synektik’s strategic initiatives, product portfolio expansion, and market leadership in robotic surgery, directly aligning with its core business model of providing cutting-edge medical technologies and solutions to healthcare providers.

Synektik S.A. Announces Extraordinary General Meeting to Discuss Strategic Division

Synektik S.A., a leading Polish medical technology company, has scheduled an Extraordinary General Meeting (EGM) of Shareholders for March 19, 2026, at its headquarters in Warsaw. The meeting will address key corporate matters, including the proposed division of the company. The division involves transferring a portion of Synektik's assets to a newly established entity, SYN2BIO S.A., as part of a strategic restructuring plan.

The proposed division will see the transfer of a segment of Synektik's business, specifically related to the production of cardiomarkers and CBNC, to SYN2BIO S.A. This move is aimed at optimizing operations and focusing on core business areas. Shareholders of Synektik S.A. will receive shares in SYN2BIO S.A. in a 1:1 ratio, ensuring their proportional ownership in the new entity. The division will not affect Synektik's share capital, and the new shares will be listed on the Warsaw Stock Exchange.

The Supervisory Board of Synektik S.A. has positively endorsed the proposed resolutions, which will be presented for approval during the EGM. The company has also provided detailed procedural guidelines for shareholders to participate in the meeting and exercise their voting rights.

Relevance to Synektik S.A.: This development aligns with Synektik S.A.'s strategic focus on enhancing its operational efficiency and expanding its presence in the medical technology sector, particularly in the production of advanced diagnostic solutions.

Synektik S.A. Announces Planned Division and Asset Transfer to Syn2bio S.A.

Synektik S.A., a leading Polish medical technology company, has announced its intention to divide the company and transfer part of its assets to Syn2bio S.A., based in Warsaw. The division will involve the transfer of an organized part of Synektik's enterprise, specifically assets related to the "Kardioznacznik" and "CBNC" projects, to Syn2bio S.A. The process will be conducted in accordance with Article 529 § 1 point 4 of the Polish Commercial Companies Code (KSH).

The division plan, including all relevant documentation and an auditor's opinion, has been made publicly available on the websites of both companies and will remain accessible until the conclusion of the general meetings of both entities, where the division resolution will be adopted. The transfer will include both material and non-material assets, which are financially and organizationally distinct within Synektik's operations.

The division is part of Synektik's strategic efforts to streamline its operations and focus on its core business areas, including the production of radiopharmaceuticals, distribution of advanced medical equipment, and IT solutions for healthcare.

Relevance: This development aligns with Synektik S.A.'s business model, as it reflects the company's strategy to optimize its operations and focus on its key segments, including radiopharmaceuticals and advanced medical technologies.

Synektik S.A. Projects Growth in EBITDA and Expands Presence in New Markets

Synektik S.A., a leading Polish medical technology company, anticipates continued growth in normalized EBITDA and an increase in recurring revenues, according to Vice President Dariusz Korecki. The company plans to introduce its flagship da Vinci robotic surgical systems to the Baltic countries this year, marking a significant expansion into new markets. Additionally, Synektik expects the impact of its sales in Ukraine to become evident in the next financial year, signaling further international growth opportunities.

These developments align with Synektik's business strategy of expanding its footprint in the medical technology sector, particularly through the distribution of advanced robotic surgical systems and the provision of innovative healthcare solutions.

National Health Fund: A Key Element in Poland's Healthcare System

Dr. Piotr Bromber, a political scientist and economist, emphasizes the importance of the National Health Fund (NFZ) as a cornerstone of Poland's healthcare system in his latest book, "Narodowy Fundusz Zdrowia w systemie ochrony zdrowia. Pacjenci – Ekonomia – Polityka." With over 20 years of operation, NFZ is described as a valuable asset rather than a burden, playing a crucial role in financing healthcare services and addressing systemic challenges. Bromber highlights the need for strategic planning, improved patient satisfaction, and stable regulations to enhance NFZ's effectiveness.

While acknowledging criticisms, Bromber argues that NFZ's perceived shortcomings often stem from issues with healthcare providers rather than the fund itself. He advocates for a balanced approach that considers the perspectives of various stakeholders, including patients, policymakers, and healthcare providers. Recommendations include fostering trust, enhancing service quality, and refining the relationship between NFZ and the Ministry of Health to ensure long-term stability and efficiency.

Relevance to Synektik S.A.: The article underscores the importance of strategic healthcare financing and patient-centered approaches, aligning with Synektik S.A.'s focus on delivering advanced medical technologies and solutions that improve healthcare outcomes in Poland.

MedTech Solutions Signs Letter of Intent for Strategic Acquisition in Orthopedics and Surgery

MedTech Solutions has announced the signing of a letter of intent to acquire 100% of shares in a distribution company specializing in orthopedics and surgery. The target company, which operates in over 100 hospitals, reported a net profit of approximately PLN 1 million in 2025. The acquisition aims to strengthen MedTech Solutions' market position and lay the groundwork for further consolidation in the medical device sector.

The deal includes a term sheet expected to be finalized within 30 days, outlining key transaction parameters. The acquired company boasts a specialized four-person sales team and a portfolio of over 100 active distribution contracts with Polish hospitals, covering medical products in orthopedics and surgery. MedTech Solutions plans to integrate sales structures and leverage product synergies to optimize operational efficiency and enhance commercial effectiveness.

This acquisition marks the first step in building a larger distribution platform in the medical device segment. The process will involve due diligence and negotiation of transaction documentation, with completion contingent on meeting standard legal and formal requirements.

MedTech Solutions is listed on the NewConnect market.

Relevance to Synektik S.A.: The acquisition aligns with Synektik S.A.'s focus on distributing advanced medical technologies and solutions, highlighting the competitive landscape and opportunities for growth in the Polish healthcare market.